Tracer library / [68Ga]LW02080

[68Ga]LW02080

Also written as [Ga-68]Ga-LW02080

Radionuclide: Ga-68 t½ 67.71 min
Modality: PET
Production route: —
Stage: Reported once
Syntheses indexed: 1

Prostate cancer Preclinical only, no clinical indication yet

What it is

Compound class: DOTA-conjugated bombesin(6-14) peptide analog (GRPR antagonist)
Target / mechanism: Gastrin-releasing peptide receptor (GRPR) antagonist PMID 40006047
Clinical application: Preclinical PET imaging of GRPR-expressing tumors (PC-3 xenografts) in mice PMID 40006047
Theranostic pair: [177Lu]Lu-LW02080

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	custom manifold	HPLC+SPE	41–75% decay-corrected	>95%	LW02080 (DOTA-conjugated peptide)	40006047 2025 Pharmaceuticals (Basel) purified 68Ga (158–523 MBq) in 0.5 mL water was added into a 4-mL glass vial containing 0.7 mL of HEPES buffer (2 M, pH 5.0) and 10 μL of precursor solution (1 mM). The radiolabeling reaction was performed by microwave heating for 1 min at 100 °C, followed by purification using HPLC with a semi-preparative column. - 68Ga-labeled LW02060 and LW02080 were obtained in 41–75% decay-corrected radiochemical yields with >172 GBq/µmol molar activity and >95% radiochemical purity

Need this precursor?We can point you to suppliers for [68Ga]LW02080, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40006047. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to PET: Ga-68 is a positron emitter used only for PET imaging. Linked articles: PMID 40006047.